Japanese University Says Study on Novartis’ Blood Pressure Drug Based on Fabricated Data

A study that underlined the effectiveness of a blood pressure drug manufactured by Novartis is being withdrawn by a Japanese University.

A study that underlined the effectiveness of a blood pressure drug manufactured by Novartis is being withdrawn by a Japanese University after it admitted that the study was based on data that was fabricated.

The move was the latest chapter in a growing scandal over allegations that bogus data were used in a string of Japanese university studies for the drug Valsartan which exaggerated its effectiveness in preventing strokes and angina.

High Blood Pressure
High blood pressure or hypertension is defined as a blood pressure of above 140 mm Hg (systolic) and or 90mm Hg (diastolic).

On Wednesday, Tokyo's Jikei University School of Medicine said it would retract research that appeared in respected medical journal The Lancet six years ago.

"We will report the conclusions of our investigation to Lancet so the study can be withdrawn," a university spokesman told AFP.

The school's probe concluded that the research, led by one of Jikei's professors, relied on data analysis by an unnamed former Novartis employee, who was also involved in at least one other school's research which has been thrown into question.

Fruits to Help Lower Blood Pressure / Foods that Help Lower Blood Pressure
Top reasons why you should eat fruits to lower blood pressure and reduce the risk of heart disease. Antioxidants in fruits keep your blood pressure under control.

The fresh allegations come less than two weeks after Japan's health minister said it was very likely that tests for Valsartan were based on incomplete clinical data.

Jikei University's probe also found it had received about $85,000 worth of grants from Novartis for the study, pointing to a conflict of interest, it said.

Combination Therapy for High Blood Pressure - Monotherapy - Options - Reference
Anti-hypertensive agents are still the treatment drugs for hypertension but recent advances indicate that combination therapy may be a more effective form of treatment.

The local unit of Novartis could not be immediately reached for comment Wednesday.

On Monday, Yoshiyasu Ninomiya, head of the Swiss firm's Japanese unit, apologised for the involvement of an employee in university studies.

But he stood by other tests that said Valsartan is effective at preventing strokes and angina, as well as controlling high blood pressure.

Novartis sells the drug under the name Diovan in Japan, where it is one of the most commonly prescribed drugs on the market. It is licensed for use in more than 100 countries.

Three other Japanese universities are investigating similar claims, local media reported.

Source-AFP